by Kole Krieger | Apr 2, 2025 | Press Release
Strong potential to disrupt market for treatment of C. diff infections RePreve Trial main cohort now recruiting Seattle, WA – April 3, 2025 – In a landmark achievement for its pioneering spirulina-based drug development platform, Lumen announced today top-line results...
by admin | May 29, 2024 | Press Release
Congratulations to the Winners of the 9th Annual MTEC Membership Meeting Awards! Special Recognition Award Presented by Mr. Bill Howell, MTEC President * Winner: Dawn Rosarius, former principal assistant for acquisition MRDC for her contributions and support of MTEC...
by admin | Jan 19, 2024 | Press Release
Clostridioides difficile, commonly known as C. diff, is a significant health threat in the U.S. Recent estimates suggest that C. diff, a common bacteria, can cause infection in roughly 500,000 patients annually in the U.S., with around 30,000 of these cases resulting...
by admin | Nov 29, 2023 | Press Release
– Program aims to provide new technologies for overcoming a key biological limitation in needle-free vaccines Seattle, WA, November 29, 2023 – Lumen Bioscience—a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent...
by admin | Oct 22, 2023 | Press Release
Lumen Bioscience co-founder and CEO Brian Finrow said the company is looking for people newly diagnosed with the infection for its trials. Read More
4 ideas to kick-start U.S. drug research — and beat China in biotech
Revolutionizing the Production of Biologics with Algae
Past Wilkes Prize winners accelerate audacious climate solutions
Reviewing Real-World Safety and Efficacy Data on C difficile Therapy Rebyota